Goldman Sachs lowered its rating on MLTX from Mixed to Sell, signaling a more cautious stance on the company’s near-term prospects. The change was announced following TheFly report and reflects concerns about the valuation trajectory and competitive landscape for MoonLake’s inflammatory disease pipeline. This downgrade contrasts sharply with the stock’s recent performance and underscores Goldman’s view that downside risk now outweighs potential upside in the coming quarters.

Despite the Sell rating, MLTX shares rallied sharply, jumping nearly ten percent in a single session. The surge came on relatively light trading, with roughly 1.8 million shares exchanging hands compared to a three-month daily average closer to 5.7 million. This combination of strong price momentum and below-average turnover suggests that institutional investors may be accumulating positions ahead of key regulatory milestones.

MoonLake received encouraging feedback from the FDA regarding its lead candidate for skin disorders. In a recent Type B meeting, agency officials indicated that the company could file a Biologics License Application using existing trial data, without the need for additional clinical studies. This regulatory clarity has the potential to accelerate the approval timeline for the therapy and significantly reduce development costs, enhancing overall project economics.

Other Wall Street firms remain bullish: HC Wainwright reaffirmed its Buy recommendation and raised its target to the low-thirties, while Needham maintained its Buy stance with a target near twenty. Over the past twelve months, MLTX has traded between single-digit and mid-sixty levels, reflecting heightened volatility as investors weigh early clinical readouts and regulatory developments. The company’s market capitalization stands just above one billion dollars, making it a mid-cap player in the biopharma sector.